BE631171A - - Google Patents
Info
- Publication number
- BE631171A BE631171A BE631171DA BE631171A BE 631171 A BE631171 A BE 631171A BE 631171D A BE631171D A BE 631171DA BE 631171 A BE631171 A BE 631171A
- Authority
- BE
- Belgium
- Prior art keywords
- tryptophan
- reserpine
- composition
- composition according
- pyridoxine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 40
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 36
- 235000008160 pyridoxine Nutrition 0.000 claims description 18
- 239000011677 pyridoxine Substances 0.000 claims description 18
- 229960002862 pyridoxine Drugs 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 239000011777 magnesium Substances 0.000 claims description 10
- 229910052749 magnesium Inorganic materials 0.000 claims description 10
- 230000036772 blood pressure Effects 0.000 claims description 9
- -1 magnesium cations Chemical class 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 7
- 206010033557 Palpitations Diseases 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- ZEWQUBUPAILYHI-UHFFFAOYSA-N Trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- 241000083551 Ena Species 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N Reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 24
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 24
- 229960003147 reserpine Drugs 0.000 description 24
- 231100000486 side effect Toxicity 0.000 description 17
- 206010020772 Hypertension Diseases 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 229940091250 Magnesium supplements Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940076279 Serotonin Drugs 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 5
- 229960002672 isocarboxazid Drugs 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000036740 Metabolism Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- 230000035786 metabolism Effects 0.000 description 4
- 201000006487 neurotic disease Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010033864 Paranoia Diseases 0.000 description 3
- 208000000639 Paranoid Disorders Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001077 hypotensive Effects 0.000 description 3
- 230000001965 increased Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 2
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 Chlorpromazine Drugs 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- 229950000688 Phenothiazine Drugs 0.000 description 2
- 229960003581 Pyridoxal Drugs 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 230000000994 depressed Effects 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 201000001552 phobic disease Diseases 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- AOHMFUYIHARAGR-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;magnesium Chemical compound [Mg].[Mg].[Mg].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O AOHMFUYIHARAGR-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2H-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010004939 Bipolar I disease Diseases 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012378 Depression Diseases 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229940096405 Magnesium Cation Drugs 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L Magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 206010057840 Major depression Diseases 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004815 Meprobamate Drugs 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 241000721619 Najas Species 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010065508 Orthostatic hypertension Diseases 0.000 description 1
- 229960000964 Phenelzine Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- 229960001327 Pyridoxal Phosphate Drugs 0.000 description 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229960002324 Trifluoperazine Drugs 0.000 description 1
- 229940046001 Vitamin B Complex Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000002567 autonomic Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 201000001149 cyclothymic disease Diseases 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003001 depressive Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000002743 euphoric Effects 0.000 description 1
- 231100000592 few side effect Toxicity 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000003457 ganglion blocking agent Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000036421 sense of balance Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE631171A true BE631171A (ko) |
Family
ID=199783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE631171D BE631171A (ko) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE631171A (ko) |
-
0
- BE BE631171D patent/BE631171A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018276686B2 (en) | Use of ligustrazine nitrone derivatives in prevention and treatment of diabetic complication diseases | |
| WO2014112641A1 (ja) | 一酸化窒素濃度上昇剤 | |
| FR2620907A1 (fr) | Additif a base de magnesium pour substances nutritives, alimentaires et medicaments | |
| FR2842422A1 (fr) | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations | |
| BE1023090B1 (fr) | Composition | |
| EP3694505A1 (fr) | Composé et composition pour utilisation dans le traitement préventif et/ou curatif des maladies du système nerveux central caractérisées par un déclin de la plasticité neuronale, en particulier caractérisées par un déclin de la plasticité synaptique | |
| BE631171A (ko) | ||
| JP2015131849A (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
| WO2006042928A1 (fr) | Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent | |
| FR2922109A1 (fr) | Composition pharmaceutique ou dietetique pour inhiber l'absorption intestinale du sucre. | |
| EP3624822B1 (fr) | Principe actif constitue par un melange de composes poly-lysine et utilisation dans la prevention des avc et le traitement de la phase inflammatoire post-avc | |
| EP3027064B1 (fr) | Composition pharmaceutique, diététique ou alimentaire liquide ou semi-liquide dépourvue d'amertume contenant un sel d'arginine | |
| EP0959892B1 (fr) | Utilisation de pvp ou povidone pour diminuer le gonflement intestinal | |
| US3150044A (en) | Treatment and composition for high blood pressure and palpitation | |
| FR2845916A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine | |
| EP0334402B1 (fr) | Composition antiasthénique, son procédé de préparation et son utilisation | |
| JP2003335665A (ja) | 生体内ビタミンｃレベル調節用組成物 | |
| WO2017137767A1 (en) | Anti-neurodegenerative disease formulation containing apocynin and paeonol | |
| JPH0640901A (ja) | アセトアルデヒド毒性の抑制剤 | |
| EP3738596B1 (fr) | Composé et composition pour utilisation dans le traitement du syndrome prémenstruel et/ou du trouble dysphorique prémenstruel | |
| FR2504008A1 (fr) | Preparation pharmaceutique a base d'un melange de n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine et d'un diuretique | |
| JP2004505919A (ja) | 一次性頭痛の処置におけるビタミン配合物の使用 | |
| FR2650502A1 (fr) | Nouvelle forme galenique orale ameliorant la biodisponibilite | |
| BE829197A (fr) | Compositions anti-inflammatoires, leur preparation et leur utilisation | |
| BE1000256A6 (fr) | Composition pour le traitement de la peau, des cheveux et des ongles, son procede de preparation et son utilisation. |